UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 06/2018, Volume 391, Issue 10138, pp. 2417 - 2429
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hyponatremia - chemically induced | Furosemide - administration & dosage | Humans | Middle Aged | Male | Albumins - therapeutic use | Furosemide - adverse effects | Time Factors | Ascites - therapy | Female | Drug Therapy, Combination | Quality-Adjusted Life Years | Liver Cirrhosis - drug therapy | Ascites - etiology | Diuretics - administration & dosage | Liver Cirrhosis - complications | Kaplan-Meier Estimate | Survival Rate | Mineralocorticoid Receptor Antagonists - therapeutic use | Hyperkalemia - chemically induced | Quality of Life | Aged | Liver Cirrhosis - physiopathology | Diuretics - adverse effects | Paracentesis | Albumin | Analysis | Bacterial infections | Liver | Mortality | Medical treatment | Clinical trials | Population studies | Survival | Patients | Evidence-based medicine | Furosemide | Quality of life | Cirrhosis | Randomization | Hospitals | Motivation | Medical prognosis | Cost analysis | Ascites | Index Medicus | Abridged Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 1, pp. 145 - 172
Gastroenterology and Hepatology | Care pathway | Liver | Cholestasis | Guidelines | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Liver Transplantation | Prognosis | Humans | Cholangitis - complications | Female | Male | Cholangitis - diagnosis | Cholangitis - therapy | Practice Guidelines as Topic | Ursodeoxycholic Acid - therapeutic use | Liver cirrhosis | Care and treatment | Diagnosis | Studies | Cirrhosis | Budesonide | Hepatitis | Liver diseases | Cholangitis | Gallbladder diseases | Derivatives | Patients | Ursodeoxycholic acid | Index Medicus
Journal Article
Infection, ISSN 0300-8126, 10/2018, Volume 46, Issue 5, pp. 607 - 615
Cirrhosis | Ombitasvir | Medicine & Public Health | General Practice / Family Medicine | Infectious Diseases | Internal Medicine | Paritaprevir | Elderly | Dasabuvir | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Uracil - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Female | Drug Therapy, Combination | Liver Cirrhosis - etiology | Liver Cirrhosis - diagnosis | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Anilides - administration & dosage | Antiviral Agents - adverse effects | Biomarkers | Aged | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Complications and side effects | Research | Hepatitis C | Drug therapy | Liver cirrhosis | Risk factors | Hypertension | Effectiveness | Liver diseases | Ritonavir | Health risks | Viruses | Pharmacology | Bilirubin | Multivariate analysis | Ribonucleic acid--RNA | Patients | Ribavirin | Hepatitis | Patient safety | Safety | Hepatitis C virus | Genotypes | Index Medicus
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 01/2019, Volume 69, Issue 1, pp. 420 - 430
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Cell Proliferation | Humans | Translational Medical Research | Liver Diseases - complications | Hepatocytes - pathology | Bile Ducts - pathology | Hyperplasia - etiology | Animal models | Liver diseases | Fatty liver | Hepatocytes | Therapeutic applications | Hyperplasia | Stem cells | Fibrosis | Progenitor cells | Bile duct | Bile | Index Medicus
Journal Article
Gut, ISSN 0017-5749, 09/2018, Volume 67, Issue 9, pp. 1565 - 1567
cholestatic liver diseases | bile acid | glucagen-like peptides | primary sclerosing cholangitis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Fibroblast growth factor | Active transport | Peptides | Glucagon | Liver | Homeostasis | Intracellular signalling | Proteins | Signal transduction | Microbiota | Hepatology | Rodents | Fibroblasts | Fibroblast growth factor receptor 4 | Colon | Resins | Growth factors | Glucagon-like peptide 1 | Enzymes | Liver diseases | Multidrug resistance | Hydroxylase | Cholangitis | Ileum | Cholesterol | Studies | Acids | Sodium | Large intestine | Intracellular | Bile | Index Medicus | Abridged Index Medicus
Journal Article
Liver international, ISSN 1478-3223, 06/2020, Volume 40, Issue 6, pp. 1408 - 1414
non‐invasive markers | prognostic markers | macrophage activation markers | primary biliary cholangitis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Alkaline phosphatase | Prognosis | Liver diseases | Syngeneic grafts | Liver | Markers | Cholangitis | Mannose | Transplantation | Regression analysis | Macrophages | CD163 antigen | Receptors | Cell activation | Allografts | Fibrosis | Liver transplantation | Index Medicus
Journal Article
Nature reviews. Gastroenterology & hepatology, ISSN 1759-5045, 05/2016, Volume 13, Issue 5, pp. 261 - 280
Liver Transplantation | Humans | Neoplasm Proteins - physiology | Intercellular Signaling Peptides and Proteins - metabolism | Tumor Microenvironment - genetics | Cell Transformation, Neoplastic - genetics | Neoplastic Stem Cells - pathology | Bile Duct Neoplasms - genetics | Stents | Molecular Targeted Therapy - methods | Cancer-Associated Fibroblasts - physiology | Macrophages - physiology | Cholangiocarcinoma - therapy | Cytokines - metabolism | Early Detection of Cancer | Risk Factors | Cell Proliferation - physiology | Signal Transduction - genetics | Forecasting | Genetic Heterogeneity | Gene Fusion - genetics | Bile Duct Neoplasms - therapy | Cholangiocarcinoma - pathology | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epigenesis, Genetic - genetics | Cholangiocarcinoma - genetics | Bile Duct Neoplasms - pathology | Neoplasm Staging | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Index Medicus
Journal Article